HSK39297

DRUG3 trials

Sponsors

Haisco Pharmaceutical Group Co., Ltd.

Conditions

HealthyIgA Nephropathy (IgAN)Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 1

A Phase I Study to Assess the Safety,Tolerability, PK, PD, and Food Effect of HSK39297 in Healthy Subjects

CompletedNCT06350279

Haisco Pharmaceutical Group Co., Ltd.Healthy

Start: 2023-12-25End: 2024-09-29Updated: 2025-01-01

Phase 2

A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）

CompletedNCT06561841

Haisco Pharmaceutical Group Co., Ltd.Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start: 2024-07-17End: 2025-04-02Updated: 2025-06-29

Phase 3

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

RecruitingNCT07390123

Haisco Pharmaceutical Group Co., Ltd.IgA Nephropathy (IgAN)

Start: 2026-04-07End: 2028-07-01Target: 370Updated: 2026-05-28

Related Papers

Efficacy and safety of HSK39297 monotherapy in patients with paroxysmal nocturnal hemoglobinuria (PNH)

Blood2025-11-03